Semaglutide Tablets for Type 2 Diabetes
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is conducted to compare four different tablets containing the investigational medicine semaglutide at the same dose. It is done to test how semaglutide in each of the tablet versions is taken up in the body. Which treatments participants will receive is decided by chance. The study will last for about 28 weeks. The study will enroll healthy male participants.
Will I have to stop taking my current medications?
Yes, you will need to stop taking any prescription or non-prescription drugs, except for routine vitamins, topical medications, and occasional use of paracetamol (acetaminophen) and ibuprofen, at least 14 days before the study starts.
Is semaglutide safe for humans?
How is the drug semaglutide unique for treating type 2 diabetes?
Semaglutide is unique because it is available as both a once-weekly injection (Ozempic) and the first oral GLP-1 receptor agonist (Rybelsus) for type 2 diabetes, offering flexibility in administration. It effectively lowers blood sugar and promotes weight loss, with the oral form using an absorption enhancer to facilitate its uptake in the body.24678
What data supports the effectiveness of the drug Semaglutide for Type 2 Diabetes?
Who Is on the Research Team?
Clinical Transparency (dept. 2834)
Principal Investigator
Novo Nordisk A/S
Are You a Good Fit for This Trial?
This trial is for healthy men who may be at risk of developing Type 2 Diabetes. Participants will be randomly assigned to receive one of four different tablet formulations of a medicine called semaglutide.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment Period 1
Participants receive subcutaneously semaglutide B followed by oral semaglutide in different sequences
Treatment Period 2
Participants continue with oral semaglutide in different sequences
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Semaglutide
Semaglutide is already approved in European Union, United States, Canada, Japan for the following indications:
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Type 2 diabetes
- Cardiovascular disease
- Obesity
- Obesity
- Type 2 diabetes
Find a Clinic Near You
Who Is Running the Clinical Trial?
Novo Nordisk A/S
Lead Sponsor
Lars Fruergaard Jørgensen
Novo Nordisk A/S
Chief Executive Officer since 2017
MSc in Finance and Business Administration, Aarhus School of Business, Aarhus University, Denmark
Martin Holst Lange
Novo Nordisk A/S
Chief Medical Officer since 2021
MD from University of Copenhagen